Cargando…
Gene therapy for Wiskott-Aldrich Syndrome—Long-term reconstitution and clinical benefits, but increased risk for leukemogenesis
Wiskott-Aldrich-Syndrome (WAS) is a rare X-linked recessive disease caused by mutations of the WAS gene. It is characterized by immunodeficiency, autoimmunity, low numbers of small platelets (microthrombocytopenia) and a high risk of cancer, especially B cell lymphoma and leukemia.
Autores principales: | Braun, Christian Joerg, Witzel, Maximilian, Paruzynski, Anna, Boztug, Kaan, von Kalle, Christof, Schmidt, Manfred, Klein, Christoph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755244/ https://www.ncbi.nlm.nih.gov/pubmed/26942098 http://dx.doi.org/10.4161/21675511.2014.947749 |
Ejemplares similares
-
Síndrome de Wiskott - Aldrich /
por: Tello Gabriel, Adriana -
Unraveling the Repertoire in Wiskott–Aldrich Syndrome
por: Petersen, Sven H., et al.
Publicado: (2014) -
Autoimmunity in Wiskott–Aldrich Syndrome: An Unsolved Enigma
por: Catucci, Marco, et al.
Publicado: (2012) -
Autoimmunity in Wiskott–Aldrich Syndrome: Updated Perspectives
por: Sudhakar, Murugan, et al.
Publicado: (2021) -
B-cell reconstitution after lentiviral vector–mediated gene therapy in patients with Wiskott-Aldrich syndrome
por: Castiello, Maria Carmina, et al.
Publicado: (2015)